Biological Psychiatry
Volume 47, Issue 4 , Pages 314-324, 15 February 2000

Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study

  • Leon Grunhaus

      Affiliations

    • Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel
    • Corresponding Author InformationAddress reprint requests to Leon Grunhaus, MD, Chair Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel 52621
  • ,
  • Pinhas N Dannon

      Affiliations

    • Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel
  • ,
  • Shaul Schreiber

      Affiliations

    • Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel
  • ,
  • Ornah H Dolberg

      Affiliations

    • Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel
  • ,
  • Revital Amiaz

      Affiliations

    • Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel
  • ,
  • Reuven Ziv

      Affiliations

    • Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel
  • ,
  • Eli Lefkifker

      Affiliations

    • Psychiatry Division, Sheba Medical Center, Ramat Gan, Israel

Received 3 February 1999; received in revised form 1 June 1999 and 20 August 1999; accepted 17 September 1999.

Abstract 

%Background: Repetitive transcranial magnetic stimulation (rTMS), a new method for the stimulation of the central nervous system, is being proposed as a potential new treatment in patients with major depressive disorder (MDD). We tested the hypothesis that rTMS would be as effective as electroconvulsive therapy (ECT) in patients with MDD.

Methods: Forty patients with MDD referred for ECT were randomly assigned to either ECT or rTMS. Repetitive transcranial magnetic stimulation was performed at 90% power of the motor threshold. The stimulation frequency was 10 Hz for either 2 sec (first eight patients) or 6 sec (final 12 patients) for 20 trains. Patients were treated for up to 20 treatment days. Electroconvulsive therapy was performed according to standard protocols.

Results: Overall patients responded best to ECT (χ2 = 3.8, p < .05). Patients with MDD and psychosis responded significantly better to ECT (χ2 = 9.2, p < .01), whereas MDD patients without psychosis responded similarly to both treatments (χ2 = 0.0, ns). The analysis of variance with repeated measures of clinical variables for the whole sample revealed significant treatment effects for both groups; however, interaction between group and treatment was seen only for the Global Assessment of Function and the Sleep assessment. When the psychosis–nonpsychosis grouping was considered, patients with psychosis responded dramatically better to ECT in all assessments, whereas those without psychosis responded similarly to both treatments.

Conclusions: Overall ECT was a more potent treatment for patients with MDD, this being particularly evident in patients with MDD and psychosis; however, in patients with MDD without psychosis the effects of rTMS were similar to those of ECT. The results we report are encouraging and support an important role for rTMS in the treatment of severe MDD; however, additional blinded studies are needed to precisely define this role.

Keywords:  TMS, ECT, MDD, transcranial magnetic stimulation, electroconvulsive therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0006-3223(99)00254-1

Biological Psychiatry
Volume 47, Issue 4 , Pages 314-324, 15 February 2000